FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 350:1495-1504 April 8, 2004 Number 15 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Editorial by Topol, E. J. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article PubMed Citation

ABSTRACT

Background Lipid-lowering therapy with statins reduces the risk of cardiovascular events, but the optimal level of low-density lipoprotein (LDL) cholesterol is unclear.

Methods We enrolled 4162 patients who had been hospitalized for an acute coronary syndrome within the preceding 10 days and compared 40 mg of pravastatin daily (standard therapy) with 80 mg of atorvastatin daily (intensive therapy). The primary end point was a composite of death from any cause, myocardial infarction, documented unstable angina requiring rehospitalization, revascularization (performed at least 30 days after randomization), and stroke. The study was designed to establish the noninferiority of pravastatin as compared with atorvastatin with respect to the time to an end-point event. Follow-up lasted 18 to 36 months (mean, 24).

Results The median LDL cholesterol level achieved during treatment was 95 mg per deciliter (2.46 mmol per liter) in the standard-dose pravastatin group and 62 mg per deciliter (1.60 mmol per liter) in the high-dose atorvastatin group (P<0.001). Kaplan–Meier estimates of the rates of the primary end point at two years were 26.3 percent in the pravastatin group and 22.4 percent in the atorvastatin group, reflecting a 16 percent reduction in the hazard ratio in favor of atorvastatin (P=0.005; 95 percent confidence interval, 5 to 26 percent). The study did not meet the prespecified criterion for equivalence but did identify the superiority of the more intensive regimen.

Conclusions Among patients who have recently had an acute coronary syndrome, an intensive lipid-lowering statin regimen provides greater protection against death or major cardiovascular events than does a standard regimen. These findings indicate that such patients benefit from early and continued lowering of LDL cholesterol to levels substantially below current target levels.

Source Information

From the Thrombolysis in Myocardial Infarction (TIMI) Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston (C.P.C., E.B., C.H.M., M.A.P.); the University of Pennsylvania, Philadelphia (D.J.R.); the University of Montreal, Montreal (J.L.R.); Bristol-Myers Squibb, Princeton, N.J. (R.B., S.V.J.); and the Nottingham Clinical Research Group, Nottingham, United Kingdom (K.A.H., A.M.S.).

This article was published at www.nejm.org on March 8, 2004.

Address reprint requests to Dr. Cannon at the TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, 75 Francis St., Boston, MA 02115, or at cpcannon{at}partners.org.

Full Text of this Article

Related Letters:

Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
van der Harst P., Voors A. A., van Veldhuisen D. J., Miller M., Gotto A. M. Jr., Paradis J.-M., LeLorier J., Auer J., Weber T., Eber B., Cannon C. P., Braunwald E.
Extract | Full Text | PDF  
N Engl J Med 2004; 351:714-717, Aug 12, 2004. Correspondence

This article has been cited by other articles:

• Giraldez, R. R., Giugliano, R. P., Mohanavelu, S., Murphy, S. A., McCabe, C. H., Cannon, C. P., Braunwald, E. (2008). Baseline Low-Density Lipoprotein Cholesterol Is an Important Predictor of the Benefit of Intensive Lipid-Lowering Therapy: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) Analysis. J Am Coll Cardiol 52: 914-920 [Abstract] [Full Text]  
• Bruschke, A. V.G., Jukema, J. W. (2008). Aggressive Therapy Is Not Always the Best Therapy. J Am Coll Cardiol 52: 921-923 [Full Text]  
• Serruys, P. W., Garcia-Garcia, H. M., Buszman, P., Erne, P., Verheye, S., Aschermann, M., Duckers, H., Bleie, O., Dudek, D., Botker, H. E., von Birgelen, C., D'Amico, D., Hutchinson, T., Zambanini, A., Mastik, F., van Es, G.-A., van der Steen, A. F.W., Vince, D. G., Ganz, P., Hamm, C. W., Wijns, W., Zalewski, A., for the Integrated Biomarker and Imaging Study-2 I, (2008). Effects of the Direct Lipoprotein-Associated Phospholipase A2 Inhibitor Darapladib on Human Coronary Atherosclerotic Plaque. Circulation 118: 1172-1182 [Abstract] [Full Text]  
• FELDMAN, L. S., BROTMAN, D. J. (2008). Perioperative statins: More than lipid-lowering?. Cleveland Clinic Journal of Medicine 75: 654-662 [Abstract] [Full Text]  
• Gill, J. M., Yingxia Chen, (2008). Quality of Lipid Management in Outpatient Care: A National Study Using Electronic Health Records. American Journal of Medical Quality 23: 375-381 [Abstract]  
• (2008). Which Statin?. Obstet Gynecol 112: 696-698 [Full Text]  
• The SEARCH Collaborative Group, (2008). SLCO1B1 Variants and Statin-Induced Myopathy -- A Genomewide Study. NEJM 359: 789-799 [Abstract] [Full Text]  
• Zoghbi, G. J., Dorfman, T. A., Iskandrian, A. E. (2008). The Effects of Medications on Myocardial Perfusion. J Am Coll Cardiol 52: 401-416 [Abstract] [Full Text]  
• Steinberg, D., Glass, C. K., Witztum, J. L. (2008). Evidence Mandating Earlier and More Aggressive Treatment of Hypercholesterolemia. Circulation 118: 672-677 [Full Text]  
• Chan, M. Y., Mahaffey, K. W., Sun, L. J., Pieper, K. S., White, H. D., Aylward, P. E., Ferguson, J. J., Califf, R. M., Roe, M. T. (2008). Prevalence, Predictors, and Impact of Conservative Medical Management for Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Who Have Angiographically Documented Significant Coronary Disease. J Am Coll Cardiol Intv 1: 369-378 [Abstract] [Full Text]  
• Woodard, J., Sassano, A., Hay, N., Platanias, L. C. (2008). Statin-Dependent Suppression of the Akt/Mammalian Target of Rapamycin Signaling Cascade and Programmed Cell Death 4 Up-Regulation in Renal Cell Carcinoma. Clin. Cancer Res. 14: 4640-4649 [Abstract] [Full Text]  
• Settergren, M., Bohm, F., Ryden, L., Pernow, J. (2008). Cholesterol lowering is more important than pleiotropic effects of statins for endothelial function in patients with dysglycaemia and coronary artery disease. Eur Heart J 29: 1753-1760 [Abstract] [Full Text]  
• DAVIDSON, M. H. (2008). Is ezetimibe/simvastatin no better than simvastatin alone? Lessons learned and clinical implications. Cleveland Clinic Journal of Medicine 75: 479-496 [Full Text]  
• White, J. R. Jr (2008). Do People With Diabetes Need Statins?. The Diabetes Educator 34: 664-673 [Abstract] [Full Text]  
• Geisler, T., Zurn, C., Paterok, M., Gohring-Frischholz, K., Bigalke, B., Stellos, K., Seizer, P., Kraemer, B. F., Dippon, J., May, A. E., Herdeg, C., Gawaz, M. (2008). Statins do not adversely affect post-interventional residual platelet aggregation and outcomes in patients undergoing coronary stenting treated by dual antiplatelet therapy. Eur Heart J 29: 1635-1643 [Abstract] [Full Text]  
• Pedersen, T. R. (2008). Overview of clinical trials on calcific aortic stenosis. Eur Heart J Suppl 10: E31-E40 [Abstract] [Full Text]  
• Shah, S. J., Waters, D. D., Barter, P., Kastelein, J. J.P., Shepherd, J., Wenger, N. K., DeMicco, D. A., Breazna, A., LaRosa, J. C. (2008). Intensive Lipid-Lowering With Atorvastatin for Secondary Prevention in Patients After Coronary Artery Bypass Surgery. J Am Coll Cardiol 51: 1938-1943 [Abstract] [Full Text]  
• Bunch, T. J., Rihal, C. S., Gumina, R. J., Cooper, L., Caplice, N. M. (2008). Progression of Nonculprit Plaque Stenosis Following Successful Percutaneous Intervention. ANGIOLOGY 59: 236-239 [Abstract]  
• Mohler, E. R. III, Ballantyne, C. M., Davidson, M. H., Hanefeld, M., Ruilope, L. M., Johnson, J. L., Zalewski, A., for the Darapladib Investigators, (2008). The Effect of Darapladib on Plasma Lipoprotein-Associated Phospholipase A2 Activity and Cardiovascular Biomarkers in Patients With Stable Coronary Heart Disease or Coronary Heart Disease Risk Equivalent: The Results of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Study. J Am Coll Cardiol 51: 1632-1641 [Abstract] [Full Text]  
• Ky, B., Burke, A., Tsimikas, S., Wolfe, M. L., Tadesse, M. G., Szapary, P. O., Witztum, J. L., FitzGerald, G. A., Rader, D. J. (2008). The Influence of Pravastatin and Atorvastatin on Markers of Oxidative Stress in Hypercholesterolemic Humans. J Am Coll Cardiol 51: 1653-1662 [Abstract] [Full Text]  
• Ambrose, J. A. (2008). In Search of the "vulnerable plaque": can it be localized and will focal regional therapy ever be an option for cardiac prevention?. J Am Coll Cardiol 51: 1539-1542 [Abstract] [Full Text]  
• Pitt, B., Loscalzo, J., Ycas, J., Raichlen, J. S. (2008). Lipid Levels After Acute Coronary Syndromes. J Am Coll Cardiol 51: 1440-1445 [Abstract] [Full Text]  
• Miller, M. (2008). Lipid Levels in the Post-Acute Coronary Syndrome Setting: Destabilizing Another Myth?. J Am Coll Cardiol 51: 1446-1447 [Full Text]  
• Howard, B. V., Roman, M. J., Devereux, R. B., Fleg, J. L., Galloway, J. M., Henderson, J. A., Howard, Wm. J., Lee, E. T., Mete, M., Poolaw, B., Ratner, R. E., Russell, M., Silverman, A., Stylianou, M., Umans, J. G., Wang, W., Weir, M. R., Weissman, N. J., Wilson, C., Yeh, F., Zhu, J. (2008). Effect of Lower Targets for Blood Pressure and LDL Cholesterol on Atherosclerosis in Diabetes: The SANDS Randomized Trial. JAMA 299: 1678-1689 [Abstract] [Full Text]  
• Kastelein, J. J.P., Akdim, F., Stroes, E. S.G., Zwinderman, A. H., Bots, M. L., Stalenhoef, A. F.H., Visseren, F. L.J., Sijbrands, E. J.G., Trip, M. D., Stein, E. A., Gaudet, D., Duivenvoorden, R., Veltri, E. P., Marais, A. D., de Groot, E., the ENHANCE Investigators, (2008). Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia. NEJM 358: 1431-1443 [Abstract] [Full Text]  
• Kastelein, J. J.P., de Groot, E. (2008). Ultrasound imaging techniques for the evaluation of cardiovascular therapies. Eur Heart J 29: 849-858 [Abstract] [Full Text]  
• Ibanez, B., Vilahur, G., Cimmino, G., Speidl, W. S., Pinero, A., Choi, B. G., Zafar, M. U., Santos-Gallego, C. G., Krause, B., Badimon, L., Fuster, V., Badimon, J. J. (2008). Rapid change in plaque size, composition, and molecular footprint after recombinant apolipoprotein A-I Milano (ETC-216) administration: magnetic resonance imaging study in an experimental model of atherosclerosis.. J Am Coll Cardiol 51: 1104-1109 [Abstract] [Full Text]  
• Lewis, E. F., Velazquez, E. J., Solomon, S. D., Hellkamp, A. S., McMurray, J. J.V., Mathias, J., Rouleau, J.-L., Maggioni, A. P., Swedberg, K., Kober, L., White, H., Dalby, A. J., Francis, G. S., Zannad, F., Califf, R. M., Pfeffer, M. A. (2008). Predictors of the first heart failure hospitalization in patients who are stable survivors of myocardial infarction complicated by pulmonary congestion and/or left ventricular dysfunction: a VALIANT study. Eur Heart J 29: 748-756 [Abstract] [Full Text]  
• Birnbaum, Y., Lin, Y., Ye, Y., Merla, R., Perez-Polo, J. R., Uretsky, B. F. (2008). Pretreatment With High-Dose Statin, But Not Low-Dose Statin, Ezetimibe, or the Combination of Low-Dose Statin and Ezetimibe, Limits Infarct Size in the Rat. J CARDIOVASC PHARMACOL THER 13: 72-79 [Abstract]  
• Josan, K. MD, Majumdar, S. R. MD MPH, McAlister, F. A. MD MSc (2008). The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials. CMAJ 178: 576-584 [Abstract] [Full Text]  
• Miller, M., Cannon, C. P., Murphy, S. A., Qin, J., Ray, K. K., Braunwald, E., for the PROVE IT-TIMI 22 Investigators, (2008). Impact of Triglyceride Levels Beyond Low-Density Lipoprotein Cholesterol After Acute Coronary Syndrome in the PROVE IT-TIMI 22 Trial.. J Am Coll Cardiol 51: 724-730 [Abstract] [Full Text]  
• Iakoubova, O. A., Sabatine, M. S., Rowland, C. M., Tong, C. H., Catanese, J. J., Ranade, K., Simonsen, K. L., Kirchgessner, T. G., Cannon, C. P., Devlin, J. J., Braunwald, E. (2008). Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study.. J Am Coll Cardiol 51: 449-455 [Abstract] [Full Text]  
• Superko, H. R., King, S. III (2008). Lipid Management to Reduce Cardiovascular Risk: A New Strategy Is Required. Circulation 117: 560-568 [Full Text]  
• Nesto, R. W. (2008). LDL Cholesterol Lowering in Type 2 Diabetes: What Is the Optimum Approach?. Clin. Diabetes 26: 8-13 [Abstract] [Full Text]  
• Baker, W. L., Gutierrez-Williams, G., White, C. M., Kluger, J., Coleman, C. I. (2008). Effect of Cinnamon on Glucose Control and Lipid Parameters. Diabetes Care 31: 41-43 [Abstract] [Full Text]  
• Kinlay, S., Schwartz, G. G., Olsson, A. G., Rifai, N., Szarek, M., Waters, D. D., Libby, P., Ganz, P., for the Myocardial Ischemia Reduction with Aggress, (2008). Inflammation, Statin Therapy, and Risk of Stroke After an Acute Coronary Syndrome in the MIRACL Study. Arterioscler. Thromb. Vasc. Bio. 28: 142-147 [Abstract] [Full Text]  
• American Diabetes Association, (2008). Standards of Medical Care in Diabetes--2008. Diabetes Care 31: S12-S54 [Full Text]  
• Kaneda, A., Wang, C. J., Cheong, R., Timp, W., Onyango, P., Wen, B., Iacobuzio-Donahue, C. A., Ohlsson, R., Andraos, R., Pearson, M. A., Sharov, A. A., Longo, D. L., Ko, M. S. H., Levchenko, A., Feinberg, A. P. (2007). Enhanced sensitivity to IGF-II signaling links loss of imprinting of IGF2 to increased cell proliferation and tumor risk. Proc. Natl. Acad. Sci. USA 104: 20926-20931 [Abstract] [Full Text]  
• O'Neil, C. E., Nicklas, T. A. (2007). State of the Art Reviews: Relationship Between Diet/ Physical Activity and Health. AMERICAN JOURNAL OF LIFESTYLE MEDICINE 1: 457-481 [Abstract]  
• Preston, R. A., Harvey, P., Herfert, O., Dykstra, G., Jukema, J. W., Sun, F., Gillen, D. (2007). A Randomized, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Pharmacodynamic Interaction of Coadministered Amlodipine and Atorvastatin in 1660 Patients With Concomitant Hypertension and Dyslipidemia: The Respond Trial. J Clin Pharmacol 47: 1555-1569 [Abstract] [Full Text]  
• Chaturvedi, S., Turan, T. N., Lynn, M. J., Kasner, S. E., Romano, J., Cotsonis, G., Frankel, M., Chimowitz, M. I., For the WASID Study Group, (2007). Risk factor status and vascular events in patients with symptomatic intracranial stenosis. Neurology 69: 2063-2068 [Abstract] [Full Text]  
• Ardigo, D., Assimes, T. L., Fortmann, S. P., Go, A. S., Hlatky, M., Hytopoulos, E., Iribarren, C., Tsao, P. S., Tabibiazar, R., Quertermous, T., for the ADVANCE Investigators, (2007). Circulating chemokines accurately identify individuals with clinically significant atherosclerotic heart disease. Physiol. Genomics 31: 402-409 [Abstract] [Full Text]  
• Shepherd, J., Kastelein, J. J.P., Bittner, V., Deedwania, P., Breazna, A., Dobson, S., Wilson, D. J., Zuckerman, A., Wenger, N. K., for the Treating to New Targets Investigators, (2007). Effect of Intensive Lipid Lowering with Atorvastatin on Renal Function in Patients with Coronary Heart Disease: The Treating to New Targets (TNT) Study. CJASN 2: 1131-1139 [Abstract] [Full Text]  
• Mudd, J. O., Borlaug, B. A., Johnston, P. V., Kral, B. G., Rouf, R., Blumenthal, R. S., Kwiterovich, P. O. Jr (2007). Beyond Low-Density Lipoprotein Cholesterol: Defining the Role of Low-Density Lipoprotein Heterogeneity in Coronary Artery Disease. J Am Coll Cardiol 50: 1735-1741 [Abstract] [Full Text]  
• Gortney, J. S., Sanders, R. M. (2007). Impact of C-reactive protein on treatment of patients with cardiovascular disease. Am J Health Syst Pharm 64: 2009-2016 [Abstract] [Full Text]  
• Marschner, I. C., Simes, R. J., Keech, A. (2007). Biases in the Identification of Risk Factor Thresholds and J-Curves. Am J Epidemiol 166: 824-831 [Abstract] [Full Text]  
• Scirica, B. M., Morrow, D. A., Cannon, C. P., de Lemos, J. A., Murphy, S., Sabatine, M. S., Wiviott, S. D., Rifai, N., McCabe, C. H., Braunwald, E., for the Thrombolysis in Myocardial Infarction (TIM, (2007). Clinical Application of C-Reactive Protein Across the Spectrum of Acute Coronary Syndromes. Clin. Chem. 53: 1800-1807 [Abstract] [Full Text]  
• Ferreira, G. A., Navarro, T. P., Telles, R. W., Andrade, L. E. C., Sato, E. I. (2007). Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: an 8 weeks controlled trial. Rheumatology (Oxford) 46: 1560-1565 [Abstract] [Full Text]  
• Laudi, S., Trump, S., Schmitz, V., West, J., McMurtry, I. F., Mutlak, H., Christians, U., Weimann, J., Kaisers, U., Steudel, W. (2007). Serotonin transporter protein in pulmonary hypertensive rats treated with atorvastatin. Am. J. Physiol. Lung Cell. Mol. Physiol. 293: L630-L638 [Abstract] [Full Text]  
• Donahoe, S. M., Stewart, G. C., McCabe, C. H., Mohanavelu, S., Murphy, S. A., Cannon, C. P., Antman, E. M. (2007). Diabetes and Mortality Following Acute Coronary Syndromes. JAMA 298: 765-775 [Abstract] [Full Text]  
• Singh, I. M., Shishehbor, M. H., Ansell, B. J. (2007). High-Density Lipoprotein as a Therapeutic Target: A Systematic Review. JAMA 298: 786-798 [Abstract] [Full Text]  
• Anderson, J. L., Adams, C. D., Antman, E. M., Bridges, C. R., Califf, R. M., Casey, D. E. Jr, Chavey, W. E. II, Fesmire, F. M., Hochman, J. S., Levin, T. N., Lincoff, A. M., Peterson, E. D., Theroux, P., Wenger, N. K., Wright, R. S., Smith, S. C. Jr, Jacobs, A. K., Adams, C. D., Anderson, J. L., Antman, E. M., Halperin, J. L., Hunt, S. A., Krumholz, H. M., Kushner, F. G., Lytle, B. W., Nishimura, R., Ornato, J. P., Page, R. L., Riegel, B. (2007). ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 50: e1-e157 [Full Text]  
• Anderson, J. L., Adams, C. D., Antman, E. M., Bridges, C. R., Califf, R. M., Casey, D. E. Jr, Chavey, W. E. II, Fesmire, F. M., Hochman, J. S., Levin, T. N., Lincoff, A. M., Peterson, E. D., Theroux, P., Wenger, N. K., Wright, R. S., Smith, S. C. Jr, Jacobs, A. K., Adams, C. D., Anderson, J. L., Antman, E. M., Halperin, J. L., Hunt, S. A., Krumholz, H. M., Kushner, F. G., Lytle, B. W., Nishimura, R., Ornato, J. P., Page, R. L., Riegel, B. (2007). ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 50: 652-726 [Full Text]  
• Leeper, N. J., Ardehali, R., deGoma, E. M., Heidenreich, P. A. (2007). Statin Use in Patients With Extremely Low Low-Density Lipoprotein Levels Is Associated With Improved Survival. Circulation 116: 613-618 [Abstract] [Full Text]  
• Momin, A., Melikian, N., Wheatcroft, S. B., Grieve, D., John, L. C., El Gamel, A., Marrinan, M. T., Desai, J. B., Driver, C., Sherwood, R., Shah, A. M., Kearney, M. T. (2007). The association between saphenous vein endothelial function, systemic inflammation, and statin therapy in patients undergoing coronary artery bypass surgery. J. Thorac. Cardiovasc. Surg. 134: 335-341 [Abstract] [Full Text]  
• Afilalo, J., Majdan, A. A, Eisenberg, M. J (2007). Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomised controlled trials. Heart 93: 914-921 [Abstract] [Full Text]  
• Yu, C.-M., Zhang, Q., Lam, L., Lin, H., Kong, S.-L., Chan, W., Fung, J. W.-H., Cheng, K. K K, Chan, I. H.-S., Lee, S. W.-L., Sanderson, J. E, Lam, C. W.-K. (2007). Comparison of intensive and low-dose atorvastatin therapy in the reduction of carotid intimal-medial thickness in patients with coronary heart disease. Heart 93: 933-939 [Abstract] [Full Text]  
• Choudhry, N. K, Levin, R., Winkelmayer, W. C (2007). Statins in elderly patients with acute coronary syndrome: an analysis of dose and class effects in typical practice. Heart 93: 945-951 [Abstract] [Full Text]  
• Packard, R. R. S., Schlegel, S., Senouf, D., Burger, F., Sigaud, P., Perneger, T., Siegrist, C.-A., Mach, F. (2007). Atorvastatin Treatment and Vaccination Efficacy. J Clin Pharmacol 47: 1022-1027 [Full Text]  
• Alsheikh-Ali, A. A., Maddukuri, P. V., Han, H., Karas, R. H. (2007). Effect of the Magnitude of Lipid Lowering on Risk of Elevated Liver Enzymes, Rhabdomyolysis, and Cancer: Insights From Large Randomized Statin Trials. J Am Coll Cardiol 50: 409-418 [Abstract] [Full Text]  
• Angiolillo, D. J., Alfonso, F. (2007). Clopidogrel Statin Interaction: Myth or Reality?. J Am Coll Cardiol 50: 296-298 [Full Text]  
• Wenger, N. K., Lewis, S. J., Herrington, D. M., Bittner, V., Welty, F. K., for the Treating to New Targets Study Steering Com, (2007). Outcomes of Using High- or Low-Dose Atorvastatin in Patients 65 Years of Age or Older with Stable Coronary Heart Disease. ANN INTERN MED 147: 1-9 [Abstract] [Full Text]  
• Sipahi, I., Tuzcu, E. M., Wolski, K. E., Nicholls, S. J., Schoenhagen, P., Hu, B., Balog, C., Shishehbor, M., Magyar, W. A., Crowe, T. D., Kapadia, S., Nissen, S. E. (2007). {beta}-Blockers and Progression of Coronary Atherosclerosis: Pooled Analysis of 4 Intravascular Ultrasonography Trials. ANN INTERN MED 147: 10-18 [Abstract] [Full Text]  
• Nogueira, J., Weir, M. (2007). The Unique Character of Cardiovascular Disease in Chronic Kidney Disease and Its Implications for Treatment with Lipid-Lowering Drugs. CJASN 2: 766-785 [Abstract] [Full Text]  
• Chatzizisis, Y. S., Coskun, A. U., Jonas, M., Edelman, E. R., Feldman, C. L., Stone, P. H. (2007). Role of Endothelial Shear Stress in the Natural History of Coronary Atherosclerosis and Vascular Remodeling: Molecular, Cellular, and Vascular Behavior. J Am Coll Cardiol 49: 2379-2393 [Abstract] [Full Text]  
• Ray, K. K., Morrow, D. A., Sabatine, M. S., Shui, A., Rifai, N., Cannon, C. P., Braunwald, E. (2007). Long-Term Prognostic Value of Neopterin: A Novel Marker of Monocyte Activation in Patients With Acute Coronary Syndrome. Circulation 115: 3071-3078 [Abstract] [Full Text]  
• Lindgren, P., Graff, J., Olsson, A. G., Pedersen, T. J., Jonsson, B., on behalf of the IDEAL Trial Investigators, (2007). Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin. Eur Heart J 28: 1448-1453 [Abstract] [Full Text]  
• Marz, W., Seelhorst, U., Wellnitz, B., Tiran, B., Obermayer-Pietsch, B., Renner, W., Boehm, B. O., Ritz, E., Hoffmann, M. M. (2007). Alanine to Serine Polymorphism at Position 986 of the Calcium-Sensing Receptor Associated with Coronary Heart Disease, Myocardial Infarction, All-Cause, and Cardiovascular Mortality. J. Clin. Endocrinol. Metab. 92: 2363-2369 [Abstract] [Full Text]  
• Authors/Task Force Members, , Ryden, L., Standl, E., Bartnik, M., Berghe, G. V. d., Betteridge, J., de Boer, M.-J., Cosentino, F., Jonsson, B., Laakso, M., Malmberg, K., Priori, S., Ostergren, J., Tuomilehto, J., Thrainsdottir, I., Other Contributors, , Vanhorebeek, I., Stramba-Badiale, M., Lindgren, P., Qiao, Q., ESC Committee for Practice Guidelines (CPG), , Priori, S. G., Blanc, J.-J., Budaj, A., Camm, J., Dean, V., Deckers, J., Dickstein, K., Lekakis, J., McGregor, K., Metra, M., Morais, J., Osterspey, A., Tamargo, J., Zamorano, J. L., Document Reviewers, , Deckers, J. W., Bertrand, M., Charbonnel, B., Erdmann, E., Ferrannini, E., Flyvbjerg, A., Gohlke, H., Juanatey, J. R. G., Graham, I., Monteiro, P. F., Parhofer, K., Pyorala, K., Raz, I., Schernthaner, G., Volpe, M., Wood, D. (2007). Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J Suppl 9: C3-C74 [Full Text]  
• Sugita, M., Sugita, H., Kaneki, M. (2007). Farnesyltransferase Inhibitor, Manumycin A, Prevents Atherosclerosis Development and Reduces Oxidative Stress in Apolipoprotein E-Deficient Mice. Arterioscler. Thromb. Vasc. Bio. 27: 1390-1395 [Abstract] [Full Text]  
• Tuzcu, E. M., Nicholls, S. J. (2007). Statins: Targeting Inflammation by Lowering Low-Density Lipoprotein?. J Am Coll Cardiol 49: 2010-2012 [Full Text]  
• Alexander, K. P., Newby, L. K., Armstrong, P. W., Cannon, C. P., Gibler, W. B., Rich, M. W., Van de Werf, F., White, H. D., Weaver, W. D., Naylor, M. D., Gore, J. M., Krumholz, H. M., Ohman, E. M. (2007). Acute Coronary Care in the Elderly, Part II: ST-Segment-Elevation Myocardial Infarction: A Scientific Statement for Healthcare Professionals From the American Heart Association Council on Clinical Cardiology: In Collaboration With the Society of Geriatric Cardiology. Circulation 115: 2570-2589 [Abstract] [Full Text]  
• Chan, P. S., Nallamothu, B. K., Gurm, H. S., Hayward, R. A., Vijan, S. (2007). Incremental Benefit and Cost-Effectiveness of High-Dose Statin Therapy in High-Risk Patients With Coronary Artery Disease. Circulation 115: 2398-2409 [Abstract] [Full Text]  
• (2007). Which statin, what dose?. DTB 45: 33-37 [Abstract] [Full Text]  
• Garg, A., Simha, V. (2007). Update on Dyslipidemia. J. Clin. Endocrinol. Metab. 92: 1581-1589 [Abstract] [Full Text]  
• Yanai, H., Yoshida, H., Tomono, Y., Tada, N. (2007). Atherosclerosis imaging in statin intervention trials. QJM 100: 253-262 [Full Text]  
• Davidson, M. H., Robinson, J. G. (2007). Safety of Aggressive Lipid Management. J Am Coll Cardiol 49: 1753-1762 [Abstract] [Full Text]  
• Morrow, D. A., Scirica, B. M., Karwatowska-Prokopczuk, E., Murphy, S. A., Budaj, A., Varshavsky, S., Wolff, A. A., Skene, A., McCabe, C. H., Braunwald, E., For the MERLIN-TIMI 36 Trial Investigators, (2007). Effects of Ranolazine on Recurrent Cardiovascular Events in Patients With Non-ST-Elevation Acute Coronary Syndromes: The MERLIN-TIMI 36 Randomized Trial. JAMA 297: 1775-1783 [Abstract] [Full Text]  
• Kastelein, J. J.P., van Leuven, S. I., Burgess, L., Evans, G. W., Kuivenhoven, J. A., Barter, P. J., Revkin, J. H., Grobbee, D. E., Riley, W. A., Shear, C. L., Duggan, W. T., Bots, M. L., the RADIANCE 1 Investigators, (2007). Effect of Torcetrapib on Carotid Atherosclerosis in Familial Hypercholesterolemia. NEJM 356: 1620-1630 [Abstract] [Full Text]  
• Tardif, J.-C., Gregoire, J., L'Allier, P. L., Ibrahim, R., Lesperance, J., Heinonen, T. M., Kouz, S., Berry, C., Basser, R., Lavoie, M.-A., Guertin, M.-C., Rodes-Cabau, J., for the Effect of rHDL on Atherosclerosis-Safety a, (2007). Effects of Reconstituted High-Density Lipoprotein Infusions on Coronary Atherosclerosis: A Randomized Controlled Trial. JAMA 297: 1675-1682 [Abstract] [Full Text]